

Breast Fine Needle Aspiration Cytology In a Nigerian Tertiary Hospital

O.I. Alatise¹, O.O. Lawal¹, O.O. Olasode², A.R.K. Adesunkanmi¹,

¹Department of Surgery, ²Department Of Pathology College of Health Sciences, Oau, Ile-Ife, Nigeria

Corresponding to: Dr. Alatise O.I, Department of surgery, P.M.B 5538, Ile Ife, Osun state, Nigeria.

E mail: segunalatishe@yahoo.co.uk

Objectives: Breast disease remains a major public health issue worldwide. It is the most common cancer among Nigerian women. Fine needle aspiration cytology (FNAC) is an important preoperative assessment tool along with clinical and mammography examination in both screen detected and symptomatic breast disease. This study provide opportunity to determining the accuracy of FNAC and factors affecting false negative rate in Obafemi Awolowo University Teaching Hospital complex, Ile-Ife, Osun state Nigeria

Method: All patients seen in the breast clinic with lump were sent to the pathology department for FNAC from January 1997 to December 2004. The sociodemographic data; cytology result, final histology result and the clinical staging for breast cancer were analyzed.

Results: Eight hundred and sixty-four patients had FNAC during the studied period, however only 632 cases had available final histological report. Of these, 20 (3.2%) were male while 612 (96.8%) were female, the age ranged from 15 years to 99 years, median of 36.50. We found that absolute sensitivity for malignancy to be 70.8%. The false negative rate was 14.9%, while the false positive rate was 1.8%. The suspicious rate was 9.8% while the inadequate rate was 5.4%.

Conclusion: FNAC remains the least invasive, the most rapid and the most cost effective method to confirm clinical and radiological suspicion of malignancy, however, the test has high false negative rate. We recommend that consultation between pathologists and the clinicians should be facilitated and encouraged to reduce the high false negative. Also, multi-disciplinary audits of difficult case should be part of the work routine.

Introduction

The interest in breast diseases stems from the concern aroused in patients and clinician following the diagnosis of breast cancer¹. While the overall mortality due to breast cancer has been on the decline in the developed world due to early detection and treatment^{2,3}, the reverse is the case in Nigeria and most of the developing countries⁴⁻⁷. Indeed, breast cancer is the most common female cancer in Nigeria and patients present late with the very advanced stages of the disease⁸.

Fine needle aspiration cytology (FNAC) has been used as a preoperative assessment tool together with clinical and mammographic examination in both screen detected and symptomatic breast disease⁹. It is relatively less invasive, rapid and cost effective in confirming a clinical or radiological suspicion of malignancy¹⁰. It has been reported to be a

very sensitive and specific test^{11, 12}, however, it is examiner dependent in that predictive results depend on who performs the aspiration, whether a clinician or a cytopathologist^{12,13}. This article is a presentation of how FNAC has been useful in diagnosing breast lumps at Obafemi Awolowo University Teaching Hospital complex [OAUTHC], Ile-Ife, Osun state Nigeria

Patients and Methods

Consecutive patients complaining of breast lumps seen between January 1997 and December 2004 at the surgical outpatient clinic of OAUTHC Ile Ife, Osun state, Nigeria and who had FNAC done were recruited for studying. They also included patients who had severe mastalgia and had FNAC under ultrasound guidance. The hospital is a tertiary referral center which serves the health needs of the semi-urban and rural communities of Osun, Ekiti, and Ondo states in southwestern

Nigeria. All patients were duly informed and consented. The procedure was carried out, according to standard guidelines as described by the National Health Service (NHS) Breast Screening Programme¹⁴, in the morbid anatomy department by resident and consultant pathologist. Following an aspirate, thin smears on three or four duly labeled slides were prepared and stained using Haematoxylin and Eosin [H &E] stains. The samples were reported based on NHS Breast Screening Programme¹⁴ protocol having the C1 defined as inadequate or unsatisfactory smear; C2-benign cells present; C3-mild atypia within some cells but probably benign; C4-suspicious of malignancy; C5-malignant cells present. Those patients suspected on clinical grounds to have mitotic lesions and those in whom cytopathology results were inconclusive also had incisional biopsies. The histopathological findings of the patients who had excisional biopsy or incisional biopsy or mastectomy were compared with

their cytopathology reports. The final histological diagnosis was based on examination of the formalin fixed, paraffin embedded and Haematoxylin and Eosin stained sections of the biopsy. The definitions employed were those used by the NHS breast screening Programme and these are reproduced in Table 1^{15, 16}. Staging was done using the Manchester classification [UICC 1960]. The data was analyzed using SPSS 11.0 statistical software package.

Results

There were 864 patients with breast lumps who had FNAC during the study period but only 632 of them had corresponding histopathological report for comparison. Of these, 20 (3.2%) were males while 612 (96.8%) were females. Their ages ranged from 15 to 99 years with a mean age of 39.3 (Standard Deviation=16.2 and median of 36.5 years). The overall audit results are summarized in Table 2.

Table 1. Definition of sensitivity and specificity used in the cytology quality assurance audit routine

Performance measures	Definition
Absolute sensitivity	The number of C5 [cytologically diagnosed carcinomas) diagnosed as such expressed as a percentage of the total number of histologically confirmed carcinomas including inadequate samples
Complete sensitivity	The number of C2-5 (atypia/suspicious/carcinomas) expressed as a percentage of the total number of carcinomas
Specificity	The number of correctly identified benign lesions expressed as a percentage of the total number of benign lesions sampled
PPV of C5	The number of correctly identified carcinomas expressed as a percentage of C5
PPV of C4 (suspicious)	The number of carcinomas identified as C4 (suspicious) expressed as a percentage of the total number of C4
PPV of C3 (atypia, uncertain significance)	The number of carcinomas identified as C3 (uncertain) expressed as a percentage of the total number of C3.
False-negative rate	Cases found to be carcinomas that were originally classified as C2 expressed as a percentage of the total number of carcinomas
False-positive rate	Cases found to be benign that were originally classified as C5 expressed as a percentage of the total number of carcinomas
Suspicious rate (C3-4)	Number of C3-4 expressed as a percentage of the total number of cases
Inadequate rate	Number of C1 expressed as a percentage of the total number of cases

PPV-Positive predictive value

Table 2. Summary of Audit Findings

	C1	C2	C3	C4	C5
Total Number	48	425	22	88	281
Percentage of total	5.6	49.2	2.5	10.2	32.5
No follow-up histology	14	121	8	40	57
Benign histology	14	254	8	6	6
Malignant histology	20	50	6	42	218

Table 3. Final Histological Diagnosis

Cases	Frequency	Percentage
Breast Cancer	336	53.2
Fibroadenoma	150	23.7
Fibrocystic disease of the breast	92	14.6
Breast abscess	30	4.7
Ductal papilloma	10	1.6
Keratinous cyst	6	0.9
Gynaecomastia	8	1.3
Total	632	100.0

Table 4. Measures of Performance of Cytological diagnosis

Measure of Performance	Results
Absolute sensitivity for malignancy C5	70.8%
Complete sensitivity	79.2%
Specificity	88.2%
Number of false positive cases	6
Number of false Negative cases	50
False positive rate for C5	1.8%
False negative rate for C5	14.9%
PPV1 of C5 for malignancy	97%
PPV of C4 for Malignancy	87.5%
PPV of C3 for malignancy	42.9%
Suspicious rate	9.8%
Inadequate Rate	5.4%

Table 5. Distribution of the clinical staging and cytological Diagnosis

Clinical staging	C1	C2	C3	C4	C5	Total
1	6	14	0	4	4	28
2	8	18	6	22	39	93
3	2	15	0	14	93	124
4	4	2	0	2	83	91
Total	20	9	6	42	218	336

Likelihood Ratio: 114.545 df 12 p = 000

Table 6. Age Distribution versus False Negative Rate

Age	Accurate	False Negative
<20	76	2
21-50	374	30
>50	132	18
Total	582	50

Likelihood Ratio: 6.634 df 2 P = 0.036

The various final histological diagnoses are presented in Table 3. The most common histological diagnosis in this series was breast cancer in 336 (53.2%) of cases. This was followed by fibroadenoma in 150 (23.7%) and fibrocystic disease of the breast in 92 (14.5%).

Using the final histological diagnoses as the standard, it would be noted that absolute sensitivity for malignancy was 70.8% (Table 4). The false negative rate for C5 (cytologically malignant smears) was 14.9%, while the false positive rate for C5 was 1.8%. The suspicious rate was 9.8% while the inadequate rate was 5.4%. Of the 48 with C4 (suspicious smears), 42(87.5%) were found to be malignant on histological examination. Among the C4 lesions confirmed to be benign on histology, there were 2 (4.2%) cases of fibrocystic disease, 4 (8.3%) cases of fibroadenoma. Similarly, of the 14 with C3 (atypia smears), 6(42.8%) were breast cancer, 6(42.8%) fibrocystic disease and 2(14.4%) fibroadenoma. Table 5 compares the cytological diagnoses of the malignant cases. The implication of the high false negative rate was that a few patients that presented with early breast cancer were missed. These patients will likely present with features of advanced disease on a latter date. Most

with the clinical staging (Manchester staging). As expected, it was found that the higher the staging, the higher the chances of making the cytological diagnosis of malignant condition. The age distribution of cases of false negatives was shown in (Table 6). It appeared that patients within the age 20 – 50 years with malignant lesion were more likely to be missed by cytology than other age brackets (X=6.634 df 2 P= 0.036).

Discussion

In this study, we found the absolute sensitivity for malignancy to be 70.8%, complete sensitivity of 79.2% and specificity of 88.2%. Similarly, the false negative rate for C5 was 14.9%, the false positive rate for C5 was 1.8% and the inadequate rate was 5.4%. These figures are comparable to data from some studies done in other centres^{11-12, 17-19}. However, the false negative rate is relatively high with marginally high false positive rate.

patients with breast cancer in this environment present with the late stage of the disease²⁰. Late presentation in this environment has been attributed to prolonged denial and poverty. Fear of mastectomy is another major problem

detering early presentation of women with breast cancer^{21,22}. This, occasionally, may lead to seeking alternative modes of therapy such as herbal preparations and visiting spiritual houses in an effort to avoid the disfigurement of mastectomy. In a little way, the high false negative rate of this test may also contribute to this phenomenon. This has been related to sampling error and also the difficulty in performing required standard staining procedures such as Papanicolaou and Giemsa methods, in our laboratory. Inadequate funding of the laboratories in the country may account for the unavailability of these stains. Inappropriate staining will ultimately lead to interpretation error by the cytopathologist. Moreover, the interpretation error is found to be higher the some histological types of cancer especially lobular and tubular cancer, in patient below age 40 years, tumours of less than 2cm in diameter and early breast cancer^{19,23}.

Another reason for the high false negative rate in our study could be due to sampling error. This can be minimized by proper localization and aspiration technique²³. Proper localization can be aided using ultrasound, stereotatic x-ray guided technique and the use of perforated or fenestrated plate²⁴⁻²⁶. Another disturbing finding in this series is the marginally high false positive rate. This portends unnecessary extensive surgery in some of our patients which is associated with physical and psychological morbidity.

Sequel to the shortcoming associated with FNAC, there has been a reduction in the use of this procedure for diagnosing breast cancer in developed countries .The use of FNAC is now limited to providing accurate and rapid diagnoses for women and men with benign changes and metastatic diseases²⁷. Core biopsy [CB] has largely superseded FNACB in most developed countries. The specificity and the sensitivity of CB are much higher with bearable false negative and false positive rates²⁸. Several innovations have gone into the use of CB so as to make the procedure simpler and less often associated complications²⁹. Most of the innovative biopsy forceps are not

available in a developing country like ours. Moreover, histopathology results take up to seven to fourteen days before they are available. In our environment, FNACB still remains the cheapest and fastest alternatives for first line patient management. The cost of FNAC is about N750.00 [\$5] as compared to N7, 000 to N10, 000[\$48-\$68] for surgical tissue biopsy. This should have a greater impact in developing country with limited resources and poor health care insurance coverage.

Diagnostic accuracy of the report is highly dependent on the training and experience of the cytopathologist³⁰. It is advised that caution should be employed when dealing with suspicious lesions at an early stage and in younger individuals. To improve the diagnostic accuracy of FNAC, feedback information of follow up and histology from all cases must be made available as soon as possible. Consultation between pathologists and clinicians should be facilitated and encouraged. Also, multi-disciplinary audit of difficult case should be part of the work routine. Moreover, the use of autocytofix and liquid based cytology can help to increase smear cellularity, reduce erythrocyte load and air drying artefact and eventual improvement in the diagnostic accuracy³¹

Conclusion

In conclusion, FNAC remains the least invasive, the most rapid and the most cost effective method to confirm clinical and radiological suspicion of malignancy, however, the test has high false negative rate.

References

1. Veronesi U., Boyle P., Goldhisch A, Orecchia A, Viola C. Breast cancer. *Lancet* 2005; 365:1721-41.
2. Boyle P, Ferley J. Cancer incidence and mortality in Europe, 2004. *Ann. Oncol.* 2005; 355: 1822.
3. Schairer C, Mink PJ, Caroll L, Devesa SS. Probabilities of death from

- breast cancer and other casues among female breast cancer patients. *J. Natl Cancer Inst.* 2004; 86: 1311-21.
4. Otu AA, Ekanem IO, Khalil MI, Ekpo MD, Attah EB. Characterization of breast cancer subgroups in an African population. *Br J Surg* 1989; 76: 182-184.
 5. Hisham AN, Yip CH. Overview of breast cancer in Malaysian women: a problem of late diagnosis. *Asian J Surg* 2004; 27: 130-133.
 6. Laudico AV, Esteban DB, Reyes LM. Breast cancer incidence in Metro Manila and Rizal province: 1980-1992. *Philipp J Surg Spec* 1998; 53: 151-156.
 7. Ihekwa FN. Breast cancer in Nigerian Women. *Br J Surg* 1992; 79: 771-5.
 8. Adebamowo CA, Ajayi OO. Breast cancer in Nigeria. *West Afr J* 2000; 19 [3]: 179-191.
 9. Moyes C, Dunne B. Predictive power of cytomorphological features in equivocal (C3, C4) breast FNAC. *Cytopathology* 2004; 15: 305-310.
 10. Thomas JO, Amanguno AU, Adeyi OA, Adesina OA. Fine needle aspiration [FNA] in the management of palpable masses in Ibadan: impact on the cost of care. *Cytopathology* 1999; 10: 206-210.
 11. Horgan PG, Waldron D, Mooney E, O'Brien D, McGuire R, Given HF. The role of aspiration cytological examination in diagnosis of carcinoma breast. *Surg. Gynaecol Obstet.* 1991; 172: 290-292.
 12. Dray M, Mayall F, Darlington A. Improved fine needle aspiration (FNA) cytology results with a near patient diagnosis service for breast lesions. *Cytopathology* 2000; 11: 32-37.
 13. Pleat JM, Dunkin CJS, Tam N et al. Fine needle aspiration in plastic surgery outpatients: a retrospective study. *Cytopathology* 2003; 14: 332-8.
 14. Non-operative diagnosis subgroup of the national coordinating group for breast screening pathology. Guidelines for non-operative Diagnostic Procedures and Reporting in Breast Cancer Screening. Sheffield, UK, NHSBSP publication no. 50. June 2001.
 15. Wells CA, Ellis IO, Zakhour ND, Wilson AR and the cytology subgroup of the National Coordinating Committee for Breast Cancer Screening Pathology Guidelines for cytology procedures and reporting on fine needle aspirates of the breast. *Cytopathology* 1994; 5: 316-334.
 16. Royal College of pathologist Working Party on Breast Cancer Screening (cytology subgroup). Guidelines of cytology procedures and reporting in breast cancer screening. Revised Edition November 1993 NHS screening publications. ISBN 1 871997 26 7.
 17. Royal college of Pathologists Working Group. Guidelines for Pathologist. 1989 NHS Screening Publications ISBN 1 871997 70 4.
 18. Bofin AM, Lydersen S, Isaksen C, Hagmar BM. Interpretation of fine needle aspiration cytology of the breast: a comparison of cytological, frozen section, and final histological diagnoses. *Cytopathology* 2004; 15: 297-304.
 19. Chianakwalam C, Thakur K, Bandall S, William P, Mackie M, Bales T. Risk factors for false negative breast cytology. *Br. J. Surg.* 2002; 89 Suppl. 1: 74-75.
 20. Adelusola K, Fadiran OA, Adesunkanmi ARK, Odesanmi WO. Breast cancer in Nigerian women. *Niger Med Pract* 1996; 31: 17-29.
 21. Ajekigbe AT. Fear of mastectomy: the most common factor responsible for late presentation of carcinoma of the breast in Nigeria. *Clin Oncol (R Coll Radiol)* 1991; 3: 78-80.
 22. Malik IA, Gopalan S. Use of CAM results in delay in seeking medical advice for breast cancer. *Eur J Epidemiol* 2003; 18: 817- 22
 23. McManus DT, Anderson NH. Fine needle aspiration cytology of the breast. *Current Diag Path* 2001; 7: 262-71

-
24. Gordon PB, Goldenberg SL, Chan NHL. Solid breast lesions: diagnosis with US-guided fine needle aspiration biopsy. *Radiology* 1993;189:573-580.
 25. Azavedo E, Svane G, Auer G. Stereostatic fine needle biopsy in 2594 mammographically detected non-palpable lesions. *Lancet* 1989; 1(8646):1036-6.
 26. Lofgren M, Andersson I, Bondeson L, Lindholm K. X-ray guided fine needle aspiration for the cytologic diagnosis of non-palpable breast lesions. *Cancer* 1988;61: 1032-37.
 27. Levine T. Breast cytology- Is there still a role. *Cytopathology* 2004; 15:293-296.
 28. Dennison G, Anand R, Makar SH, Pain JA. A prospective study of Fine Needle Aspiration Cytology and Core Biopsy in the Diagnosis of Breast Cancer.
 29. Meyer JE, Christian RL, Lester SC, Frenna TH, Denison CM, DiPiro PJ, Polger M. Evaluation of non-palpable solid breast masses with stereotaxic large core biopsy using a dedicated unit. *Am J of Roentgenol* 1996;167:179-82.
 30. Orell SR, Farshid G. False positive reports in fine needle biopsy of breast lesions. *Pathology* 2001; 33: 428-436.
 31. Yamashita A, Sakuma K, Shiina Y. Standardization of fine needle aspiration cytology of the breast-comparison of Autocytofix and conventional smear. *Cytopathology* 2003; 14: 79-83.